Close Menu

You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.

Home › Business, Policy & Funding › Business News › Inova Decides to End PGx Test Offerings in Response to FDA Warning Letter

Inova Decides to End PGx Test Offerings in Response to FDA Warning Letter

Apr 15, 2019
|
staff reporter

This article has been updated with a statement from the Clinical Pharmacogenetics Implementation Consortium.

NEW YORK (GenomeWeb) – Inova Health System has decided to completely stop performing its suite of pharmacogenetic tests in response to a US Food and Drug Administration warning letter.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

What's Popular?

In Regulatory News & FDA Approvals

  1. LetsGetChecked At-Home Molecular SARS-CoV-2 Test Nabs FDA Emergency Use Authorization

  2. Quest Diagnostics Receives FDA Emergency Use Authorization for COVID-19 Self-Collection Test Kit

  3. FDA Releases Reference Panel for Coronavirus Test Developers

  4. FDA Adds At-Home Self-Collection Template to SARS-CoV-2 Emergency Use Authorization Guidance

  5. Siemens Healthineers Receives CE Mark for Coronavirus Antibody Test

Sponsorships

Privacy Policy.  Terms & Conditions.  .  Copyright © 2020 GenomeWeb, a business unit of Crain Communications.  All Rights Reserved.